Department
Biographical Sketch
Lu Haiqi, Ph.D., Master’s Supervisor, Associate Chief Physician of the Medical Oncology Department. Dr. Lu obtained her doctorate in Medical Oncology from Zhejiang University in 2014. Her research interests include mechanisms of targeted therapy, immunotherapy and drug resistance in breast; signaling transduction in the development of cancer, for example Wnt/β-catenin signaling, MAPK signaling, and Hippo-YAP signaling; epigenetic regulatory mechanisms of human diseases, such as DNA methylation , histone modifications, and chromatin remodeling. Besides, she has been a visiting scholar at Kyoto University, Osaka University, and Chiba University.
Treatment Services
Comprehensive diagnosis and treatment of various common solid tumors
Specialty Interests
Mechanisms of targeted therapy, immunotherapy and drug resistance in breast cancer
Signaling transduction in the development of cancer, for example Wnt/β-catenin signaling, MAPK signaling, and Hippo-YAP signaling
Epigenetic regulatory mechanisms of human diseases, such as DNA methylation, histone modifications, and chromatin remodeling
DNA damage repair
Autophagy and mitophagy in cancer and disease
Memberships
Associate member of American Association Of Cancer Research (AACR)
Deputy secretary-general of the Youth Committee of Tumor Precision Diagnosis and Treatment of Zhejiang Anti-cancer Association
Youth member of the Medical Oncology Professional Committee of Zhejiang Anti-cancer Association
Youth member of the Tumor Metastases Professional Committee of Zhejiang Anti-cancer Association
Youth member of the Medical Chemotherapy and Biotherapy Branch of Zhejiang Medical Association
Technical Expert of Zhejiang Science and Technology Expert Database
Member of Chinese Society of Clinical Oncology(CSCO)
Member of Chinese Society of Cell Biology(CSBC)
Regular Member of the Special Committee of Breast Cancer, Chinese Anti-cancer Association.
Regular Member of the Special Committee of Tumor Etology, Chinese Anti-cancer Association
Regular Member of the Special Committee of Tumor Precision Treatment, Chinese Anti-cancer Association